EE200300246A - EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks - Google Patents

EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks

Info

Publication number: EE200300246A
Authority: EE; Estonia
Prior art keywords: osteoporosis; treatment; selective agonists; receptor selective; receptor
Prior art date: 2000-11-27

Application number

EEP200300246A

Other languages

English (en)

Inventor

O'keefe Cameron Kimberly

Allen Lefker Bruce

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-27

Filing date

2001-11-05

Publication date

2003-10-15

2001-11-05 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2003-10-15 Publication of EE200300246A publication Critical patent/EE200300246A/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EEP200300246A 2000-11-27 2001-11-05 EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks EE200300246A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25327500P	2000-11-27	2000-11-27
PCT/IB2001/002073 WO2002042268A2 (en)	2000-11-27	2001-11-05	Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (1)

Publication Number	Publication Date
EE200300246A true EE200300246A (et)	2003-10-15

Family

ID=22959588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300246A EE200300246A (et)	2000-11-27	2001-11-05	EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks

Country Status (41)

Country	Link
US (3)	US6552067B2 (et)
EP (1)	EP1339678B1 (et)
JP (2)	JP3984164B2 (et)
KR (1)	KR20030053063A (et)
CN (1)	CN1476429A (et)
AR (1)	AR035074A1 (et)
AT (1)	ATE374182T1 (et)
AU (1)	AU2002210848A1 (et)
BG (1)	BG107697A (et)
BR (1)	BR0115687A (et)
CA (1)	CA2429850C (et)
CY (1)	CY1106976T1 (et)
CZ (1)	CZ20031257A3 (et)
DE (1)	DE60130675T2 (et)
DK (1)	DK1339678T3 (et)
EA (1)	EA200300379A1 (et)
EC (1)	ECSP034623A (et)
EE (1)	EE200300246A (et)
ES (1)	ES2291361T3 (et)
GT (2)	GT200100238A (et)
HN (1)	HN2001000266A (et)
HU (1)	HUP0400807A2 (et)
IL (1)	IL155368A0 (et)
IS (1)	IS6775A (et)
MA (1)	MA26961A1 (et)
MX (1)	MXPA03004623A (et)
NO (1)	NO20032360L (et)
NZ (1)	NZ525164A (et)
OA (1)	OA12533A (et)
PA (1)	PA8533901A1 (et)
PE (1)	PE20020637A1 (et)
PL (1)	PL362030A1 (et)
PT (1)	PT1339678E (et)
SI (1)	SI1339678T1 (et)
SK (1)	SK5562003A3 (et)
SV (1)	SV2003000746A (et)
TN (1)	TNSN01166A1 (et)
TW (1)	TW200424170A (et)
UY (1)	UY27038A1 (et)
WO (1)	WO2002042268A2 (et)
ZA (1)	ZA200302803B (et)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE200300246A (et) *	2000-11-27	2003-10-15	Pfizer Products Inc.	EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
DE60221130T2 (de)	2001-07-16	2008-03-13	F. Hoffmann-La Roche Ag	2 pyrrolidon-derivate als prostanoid-agonisten
EP1409455B1 (en) *	2001-07-16	2006-01-04	F. Hoffmann-La Roche Ag	Prostaglandin analogues-as ep4 receptor agonists
KR20070043059A (ko)	2001-07-23	2007-04-24	오노 야꾸힝 고교 가부시키가이샤	Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하 질환의치료제
US20040254230A1 (en) *	2001-12-03	2004-12-16	Ogidigben Miller J.	Method for treating ocular hypertension
RU2306309C2 (ru)	2002-03-05	2007-09-20	Оно Фармасьютикал Ко., Лтд.	Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний
EP1490055A1 (en) *	2002-03-18	2004-12-29	Pfizer Products Inc.	Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
JP2005531516A (ja) *	2002-03-18	2005-10-20	ファイザー・プロダクツ・インク	選択的ｅｐ４受容体アゴニストによる治療方法
US6573294B1 (en)	2002-05-14	2003-06-03	Allergan, Inc.	8-azaprostaglandin analogs as agents for lowering intraocular pressure
US20050239872A1 (en)	2002-06-06	2005-10-27	Xavier Billot	1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
EP1513523A1 (en) *	2002-06-06	2005-03-16	Merck Frosst Canada & Co.	1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
CA2483555A1 (en) *	2002-06-10	2003-12-18	Applied Research Systems Ars Holding N.V.	Gamma lactams as prostaglandin agonists and use thereof
GB0219143D0 (en) *	2002-08-16	2002-09-25	Univ Leicester	Modified tailed oligonucleotides
JP4497320B2 (ja)	2002-10-10	2010-07-07	小野薬品工業株式会社	内因性修復因子産生促進剤
WO2004037813A1 (en) *	2002-10-25	2004-05-06	Merck Frosst Canada & Co.	Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7196082B2 (en)	2002-11-08	2007-03-27	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
US7528163B2 (en)	2002-11-08	2009-05-05	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) *	2003-03-26	2006-05-30	Merck & Co. Inc.	EP4 receptor agonist, compositions and methods thereof
JP2006515015A (ja) *	2003-01-10	2006-05-18	エフ．ホフマン−ラ　ロシュ　アーゲー	プロスタグランジンアゴニストとしての２−ピペリドン誘導体
JP4582456B2 (ja) *	2003-01-21	2010-11-17	小野薬品工業株式会社	８−アザプロスタグランジン誘導体およびその医薬用途
ES2305779T3 (es)	2003-03-03	2008-11-01	Laboratoires Serono Sa	Derivados de g-lactama como agonistas de prostaglandinas.
US6734206B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
WO2005012232A2 (en)	2003-07-18	2005-02-10	Applied Research Systems Ars Holding N.V.	Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) *	2003-08-28	2006-04-25	Adolor Corporation	Fused bicyclic carboxamide derivatives and methods of their use
EP1664011A4 (en)	2003-09-02	2009-02-25	Merck & Co Inc	OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
EP1663221A4 (en)	2003-09-04	2009-04-22	Merck & Co Inc	OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION
EP1663987B1 (en)	2003-09-04	2009-03-18	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
EP1696893A1 (en) *	2003-12-17	2006-09-06	Pfizer Products Incorporated	Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass.
US7169807B2 (en) *	2004-04-09	2007-01-30	Allergan, Inc.	10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
JP2008507521A (ja)	2004-07-20	2008-03-13	メルク　エンド　カムパニー　インコーポレーテッド	高眼圧症を治療するための眼科用組成物
WO2006043655A1 (ja)	2004-10-22	2006-04-27	Ono Pharmaceutical Co., Ltd.	吸入用医薬組成物
JP2008518013A (ja) *	2004-10-26	2008-05-29	アラーガン、インコーポレイテッド	プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
WO2006052630A1 (en) *	2004-11-04	2006-05-18	Allergan, Inc.	Therapeutic substituted piperidone compounds
US7547685B2 (en) *	2004-11-08	2009-06-16	Allergan, Inc.	Therapeutic substituted pyrrolidone compounds
US7101906B2 (en) *	2004-11-16	2006-09-05	Allergan, Inc.	2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en)	2004-11-23	2007-02-27	Allergan, Inc.	2,3,4-substituted cyclopentanones as therapeutic agents
EP1847533B1 (en) *	2005-01-27	2013-08-14	Asahi Kasei Pharma Corporation	Six-membered heterocyclic compound and the use thereof
US7531533B2 (en)	2005-01-27	2009-05-12	Asahi Kasei Pharma Corporation	6-Membered heterocyclic compound and use thereof
US7772392B2 (en)	2005-05-06	2010-08-10	Allergan, Inc.	Therapeutic substituted β-lactams
ATE515263T1 (de) *	2005-05-06	2011-07-15	Allergan Inc	Substituierte beta-lactame und deren verwendung in der medizin
US7893107B2 (en)	2005-11-30	2011-02-22	Allergan, Inc.	Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) *	2006-02-15	2006-07-19	(주)아이앤씨	수직형 대형 폐기물 파쇄기
US20070232660A1 (en) *	2006-04-04	2007-10-04	Allergan, Inc.	Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008073748A1 (en)	2006-12-08	2008-06-19	University Of Rochester	Expansion of hematopoietic stem cells
BRPI0721067A2 (pt)	2006-12-18	2014-02-25	Allergan Inc	Métodos e composições para tratar distúrbios gastrointestinais.
KR20100016299A (ko)	2007-05-08	2010-02-12	고쿠리츠다이가쿠호진 하마마츠이카다이가쿠	Ｅｐ４ 아고니스트를 함유하여 이루어지는 세포 상해성 ｔ 세포의 활성화제
PT2155733E (pt) *	2007-05-23	2013-01-07	Allergan Inc	Lactamas cíclicas para o tratamento de glaucoma ou pressão intra-ocular elevada
US8063033B2 (en) *	2008-01-18	2011-11-22	Allergan, Inc.	Therapeutic beta-lactams
US8202855B2 (en)	2008-03-04	2012-06-19	Allergan, Inc	Substituted beta-lactams
US7705001B2 (en) *	2008-03-18	2010-04-27	Allergan, Inc	Therapeutic substituted gamma lactams
EP2320906B1 (en) *	2008-08-14	2016-02-24	Beta Pharma Canada Inc.	Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010116270A1 (en)	2009-04-10	2010-10-14	Pfizer Inc.	Ep2/4 agonists
WO2011047048A1 (en)	2009-10-14	2011-04-21	Gemmus Pharma, Inc.	Combination therapy treatment for viral infections
RU2564414C2 (ru) *	2010-03-08	2015-09-27	Какен Фармасьютикал Ко., Лтд.	Новый агонист ер4
CA2738045C (en)	2010-05-28	2019-02-19	Simon Fraser University	Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (en) *	2010-06-16	2011-12-21	LEK Pharmaceuticals d.d.	Process for the synthesis of beta-amino acids and derivatives thereof
US8697057B2 (en)	2010-08-19	2014-04-15	Allergan, Inc.	Compositions and soft tissue replacement methods
EP2675491A2 (en)	2011-02-17	2013-12-25	Allergan, Inc.	Compositions and improved soft tissue replacement methods
WO2013105997A2 (en)	2011-02-23	2013-07-18	Allergan, Inc.	Compositions and improved soft tissue replacement methods
WO2013123270A1 (en)	2012-02-16	2013-08-22	Allergan, Inc.	Compositions and improved soft tissue replacement methods
WO2013123274A1 (en)	2012-02-16	2013-08-22	Allergan, Inc.	Compositions and improved soft tissue replacement methods
WO2013123275A1 (en)	2012-02-16	2013-08-22	Allergan, Inc.	Compositions and improved soft tissue replacement methods
WO2013123272A1 (en)	2012-02-16	2013-08-22	Allergan, Inc.	Compositions and improved soft tissue replacement methods
ES2612921T3 (es) *	2012-07-19	2017-05-19	Cayman Chemical Company, Incorporated	Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
US20150272874A1 (en)	2012-10-29	2015-10-01	Cardio Incorporated	Pulmonary disease-specific therapeutic agent
US9676712B2 (en)	2013-03-15	2017-06-13	Cayman Chemical Company, Inc.	Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
EP2970234B1 (en)	2013-03-15	2018-07-18	Cayman Chemical Company, Inc.	Methods of synthesizing a difluorolactam analog
KR20150130326A (ko) *	2013-03-15	2015-11-23	카이맨 케미칼 컴파니 인코포레이티드	Ep4-매개 질환 및 병태의 치료에서 사용하기 위한 ep4 수용체 선택적 효현제로서 락탐 화합물
EP3021879A2 (en) *	2013-07-19	2016-05-25	Cayman Chemical Company, Incorporated	Methods, systems, and compositions for promoting bone growth
IL280864B2 (en)	2013-08-09	2024-03-01	Ardelyx Inc	Compounds and methods for inhibiting phosphate transport
WO2015056504A1 (ja)	2013-10-15	2015-04-23	小野薬品工業株式会社	薬剤溶出性ステントグラフト
US9650414B1 (en)	2014-05-30	2017-05-16	Simon Fraser University	Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
JP6588475B2 (ja)	2014-06-06	2019-10-09	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	治療用化合物としての新規のｅｐ４アゴニスト
US9540357B1 (en)	2014-07-31	2017-01-10	Allergan, Inc.	15-aryl prostaglandins as EP4 agonists, and methods of use thereof
CN107849072B (zh)	2015-06-12	2020-12-15	西蒙弗雷泽大学	酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
CN107011377B (zh) *	2017-05-03	2019-02-26	南通书创药业科技有限公司	一种β-羰基磷酸酯的制备方法
MX2020006307A (es)	2017-12-25	2020-09-17	Asahi Kasei Pharma Corp	Compuesto ciclico de 6 miembros que contiene nitrogeno.
EP3972599A1 (en)	2019-05-21	2022-03-30	Ardelyx, Inc.	Combination for lowering serum phosphate in a patient

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1158163A (en)	1966-06-15	1969-07-16	Berk Ltd	Improvements in or relating to Polymer Compositions
ZA72645B (en) *	1971-03-05	1972-11-29	Upjohn Co	Prostaglandin analogs
DE2346706A1 (de) *	1973-09-17	1975-04-03	Hoechst Ag	Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en)	1974-08-06	1976-08-17	E. I. Du Pont De Nemours And Company	1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en)	1975-04-26	1978-09-12	Tanabe Seiyaku Co. Ltd.	8-azaprostanoic acid derivatives
NL7604330A (nl)	1975-04-28	1976-11-01	Syntex Inc	Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de)	1975-06-27	1977-01-13	Hoechst Ag	Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en)	1976-03-31	1979-11-30	Labaz	8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) *	1976-05-04	1977-11-17	Hoechst Ag	Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) *	1976-08-06	1979-12-04	Pfizer Inc.	1,5-Disubstituted-2-pyrrolidones
CA1077948A (en) *	1976-08-06	1980-05-20	Albin J. Nelson	1,-5 disubstituted-2-pyrrolidones and processes for their production
US4320136A (en)	1980-08-11	1982-03-16	E. I. Du Pont De Nemours And Company	8-Aza-16,16-difluoroprostanoids
US4456613A (en)	1982-12-27	1984-06-26	E. I. Du Pont De Nemours And Company	6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (et)	1992-03-05	1996-10-11	Pfizer
SE9302334D0 (sv)	1993-07-06	1993-07-06	Ab Astra	New compounds
ZA944647B (en)	1993-07-06	1995-01-06	Astra Ab	Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
IL113112A (en)	1994-03-28	2000-06-01	Nissan Chemical Ind Ltd	Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
US5955481A (en)	1994-03-28	1999-09-21	Nissan Chemical Industries, Ltd.	Pyridine type thiazolidines
US5703108A (en) *	1996-02-28	1997-12-30	Pfizer Inc.	Bone deposition by certain prostaglandin agonists
JP2002527400A (ja) *	1998-10-15	2002-08-27	メルクエンドカムパニーインコーポレーテッド	骨形成刺激方法
JP2002527393A (ja)	1998-10-15	2002-08-27	メルクエンドカムパニーインコーポレーテッド	骨吸収阻害方法
GEP20043203B (en) *	1999-12-22	2004-03-25	Pfizer Prod Inc	EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
ES2263557T3 (es) *	2000-01-31	2006-12-16	Pfizer Products Inc.	Uso de agonistas selectivos del receptor 4(ep4) de prostablandinas (pge2) para el tratamiento de insuficiencia renal aguda y cronica.
US20010056060A1 (en) *	2000-02-07	2001-12-27	Cameron Kimberly O.	Treatment of osteoporsis with EP2/EP4 receptor selective agonists
EE200300246A (et) *	2000-11-27	2003-10-15	Pfizer Products Inc.	EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
US6573294B1 (en) *	2002-05-14	2003-06-03	Allergan, Inc.	8-azaprostaglandin analogs as agents for lowering intraocular pressure

2001
- 2001-11-05 EE EEP200300246A patent/EE200300246A/et unknown
- 2001-11-05 PL PL01362030A patent/PL362030A1/xx not_active Application Discontinuation
- 2001-11-05 WO PCT/IB2001/002073 patent/WO2002042268A2/en active IP Right Grant
- 2001-11-05 EP EP01978757A patent/EP1339678B1/en not_active Expired - Lifetime
- 2001-11-05 CZ CZ20031257A patent/CZ20031257A3/cs unknown
- 2001-11-05 MX MXPA03004623A patent/MXPA03004623A/es active IP Right Grant
- 2001-11-05 DE DE60130675T patent/DE60130675T2/de not_active Expired - Fee Related
- 2001-11-05 ES ES01978757T patent/ES2291361T3/es not_active Expired - Lifetime
- 2001-11-05 KR KR10-2003-7007109A patent/KR20030053063A/ko not_active Application Discontinuation
- 2001-11-05 IL IL15536801A patent/IL155368A0/xx unknown
- 2001-11-05 SI SI200130776T patent/SI1339678T1/sl unknown
- 2001-11-05 AT AT01978757T patent/ATE374182T1/de not_active IP Right Cessation
- 2001-11-05 AU AU2002210848A patent/AU2002210848A1/en not_active Abandoned
- 2001-11-05 CA CA002429850A patent/CA2429850C/en not_active Expired - Fee Related
- 2001-11-05 NZ NZ525164A patent/NZ525164A/en unknown
- 2001-11-05 JP JP2002544404A patent/JP3984164B2/ja not_active Expired - Lifetime
- 2001-11-05 DK DK01978757T patent/DK1339678T3/da active
- 2001-11-05 OA OA1200300141A patent/OA12533A/en unknown
- 2001-11-05 HU HU0400807A patent/HUP0400807A2/hu unknown
- 2001-11-05 PT PT01978757T patent/PT1339678E/pt unknown
- 2001-11-05 EA EA200300379A patent/EA200300379A1/ru unknown
- 2001-11-05 BR BR0115687-0A patent/BR0115687A/pt not_active Withdrawn
- 2001-11-05 CN CNA018194877A patent/CN1476429A/zh active Pending
- 2001-11-05 SK SK556-2003A patent/SK5562003A3/sk not_active Application Discontinuation
- 2001-11-21 US US09/990,556 patent/US6552067B2/en not_active Expired - Fee Related
- 2001-11-23 UY UY27038A patent/UY27038A1/es not_active Application Discontinuation
- 2001-11-23 HN HN2001000266A patent/HN2001000266A/es unknown
- 2001-11-26 SV SV2001000746A patent/SV2003000746A/es unknown
- 2001-11-26 PE PE2001001180A patent/PE20020637A1/es not_active Application Discontinuation
- 2001-11-26 AR ARP010105489A patent/AR035074A1/es unknown
- 2001-11-26 TN TNTNSN01166A patent/TNSN01166A1/fr unknown
- 2001-11-26 TW TW093115078A patent/TW200424170A/zh unknown
- 2001-11-27 PA PA20018533901A patent/PA8533901A1/es unknown
- 2001-11-27 GT GT200100238A patent/GT200100238A/es unknown
- 2001-11-27 GT GT200100238AK patent/GT200100238AA/es unknown
2002
- 2002-12-20 US US10/326,366 patent/US6747054B2/en not_active Expired - Fee Related
2003
- 2003-04-03 BG BG107697A patent/BG107697A/xx unknown
- 2003-04-10 IS IS6775A patent/IS6775A/is unknown
- 2003-04-10 ZA ZA200302803A patent/ZA200302803B/en unknown
- 2003-05-13 MA MA27159A patent/MA26961A1/fr unknown
- 2003-05-26 NO NO20032360A patent/NO20032360L/no not_active Application Discontinuation
- 2003-05-27 EC EC2003004623A patent/ECSP034623A/es unknown
- 2003-09-23 US US10/668,633 patent/US7192979B2/en not_active Expired - Fee Related
2007
- 2007-05-11 JP JP2007127062A patent/JP2007197467A/ja active Pending
- 2007-11-06 CY CY20071101420T patent/CY1106976T1/el unknown

Also Published As

Publication number	Publication date
SK5562003A3 (en)	2004-08-03
SV2003000746A (es)	2003-01-13
BG107697A (en)	2004-01-30
CA2429850C (en)	2008-12-30
HN2001000266A (es)	2002-01-30
CA2429850A1 (en)	2002-05-30
EP1339678A2 (en)	2003-09-03
NZ525164A (en)	2005-04-29
DE60130675T2 (de)	2008-01-24
JP3984164B2 (ja)	2007-10-03
GT200100238A (es)	2002-06-26
JP2004521869A (ja)	2004-07-22
AU2002210848A1 (en)	2002-06-03
MA26961A1 (fr)	2004-12-20
US6747054B2 (en)	2004-06-08
PL362030A1 (en)	2004-10-18
DK1339678T3 (da)	2008-02-04
WO2002042268A3 (en)	2002-07-25
IL155368A0 (en)	2003-11-23
CY1106976T1 (el)	2012-09-26
EP1339678B1 (en)	2007-09-26
PT1339678E (pt)	2007-11-30
KR20030053063A (ko)	2003-06-27
HUP0400807A2 (hu)	2004-07-28
MXPA03004623A (es)	2003-09-05
SI1339678T1 (sl)	2007-12-31
CN1476429A (zh)	2004-02-18
TNSN01166A1 (fr)	2005-11-10
ATE374182T1 (de)	2007-10-15
PA8533901A1 (es)	2002-11-28
ECSP034623A (es)	2003-07-25
US20030149086A1 (en)	2003-08-07
US6552067B2 (en)	2003-04-22
AR035074A1 (es)	2004-04-14
US20040259921A1 (en)	2004-12-23
US20020065308A1 (en)	2002-05-30
NO20032360L (no)	2003-07-23
BR0115687A (pt)	2003-09-09
ES2291361T3 (es)	2008-03-01
DE60130675D1 (de)	2007-11-08
ZA200302803B (en)	2004-04-13
US7192979B2 (en)	2007-03-20
TW200424170A (en)	2004-11-16
CZ20031257A3 (cs)	2004-04-14
NO20032360D0 (no)	2003-05-26
IS6775A (is)	2003-04-10
JP2007197467A (ja)	2007-08-09
OA12533A (en)	2006-06-05
EA200300379A1 (ru)	2003-08-28
GT200100238AA (es)	2004-05-12
PE20020637A1 (es)	2002-07-18
WO2002042268A2 (en)	2002-05-30
UY27038A1 (es)	2002-07-31

Publication	Publication Date	Title
EE200300246A (et)	2003-10-15	EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
EE200200355A (et)	2003-10-15	EP4 retseptori selektiivsed agonistid osteoporoosi raviks
IS6785A (is)	2003-04-14	EP4 viðtakahindrar til meðhöndlunar á liðagigt
CY2017020I1 (el)	2017-11-14	Στεροειδη ως αγωνιστες για τους υποδοχεις fxr
DK1446379T3 (da)	2009-07-27	Arylanilin-beta2-adrenergiske receptoragonister
NO20030213D0 (no)	2003-01-16	Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
NO20030471D0 (no)	2003-01-30	Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DK1200073T3 (da)	2007-05-07	Selektive iGluR5-receptorantagonister til behandling af migræne
ITMI20001699A0 (it)	2000-07-25	Agente coesivizzante inorganico per impasti cementizi autocompattanti
DE60127712D1 (de)	2007-05-16	Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
NO20022142D0 (no)	2002-05-03	Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
ITMO20030065A0 (it)	2003-03-13	Dispositivo per l'ancoraggio di lastre ceramiche.
ES1049390Y (es)	2002-04-16	Dispositivo de anclaje para encofrados de hormigon.
ES1045721Y (es)	2001-04-01	Aparato de electromedicina
NO20002993D0 (no)	2000-06-09	FremgangsmÕte for bonuspoenganvendelse
ES1053057Y (es)	2003-06-16	Dispositivo para determinar el riesgo de riadas.
ES1046285Y (es)	2001-05-16	Dispositivo para la apertura simplificada de ampollas vitreas.
ITAR20010016A0 (it)	2001-07-10	Dispositivo sollevatore-abbassatore per bagni